StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Ruxience [legacy through FY23] by Quarter

Ruxience (rituximab biosimilar) [legacy through FY23] — International revenues ($M) ($M)

QuarterlyAnnual

Pfizer Ruxience [legacy through FY23]: $26M in Q4 2023, up 44.4% from a year earlier. That is the highest of the 14 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
26
Period ended Dec 31, 2023
Change on a year earlier
+44.4%
18 in Q4 2022
History
14 quarters
Since Q3 2020
Sources
10
Documents cited below

Where the Q4 2023 figure comes from

“|| Ruxience | 88 | 101 | (13%) | (12%) | 62 | 83 | (25%) | 26 | 18 | 43% | 46%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRuxience (rituximab biosimilar) [legacy through FY23] — International revenues ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202326+44.4%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 202319+26.7%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 202316+33.3%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 202321+90.9%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 202218+38.5%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 202215+25.0%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2022Jul 3, 202212+71.4%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2022Apr 3, 202211+22.2%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2021Dec 31, 202113+225.0%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2021Oct 3, 202112+1,100.0%Form 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2021Jul 4, 20217–Form 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2021Apr 4, 20219–Form 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗
Q4 2020Dec 31, 20204–Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
Q3 2020Sep 27, 20201–Form 8-K (Earnings / Guidance Release) (pfe-10032021xex99.htm, filed 2021-11-02) ↗

Breakdown

What makes up ruxience [legacy through FY23]

Cite this data

StockData. (2026). Pfizer Ruxience [legacy through FY23] ($M), quarterly Q3 2020–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/ruxience-leg-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.